. These CARs program highly performing effector functions that mediate potent tumor elimination 4, 8 despite the limited persistence they confer on T cells [3] [4] [5] [6] 8 . Extending their functional persistence without compromising their potency should improve current CAR therapies. Strong T cell activation drives exhaustion 9, 10 , which may be accentuated by the redundancy of CD28 and CD3ζ signaling 11, 12 as well as the spatiotemporal constraints imparted by the structure of second-generation CARs 2 . Thus, we hypothesized that calibrating the activation potential of CD28-based CARs would differentially reprogram T cell function and differentiation. Here, we show that CARs encoding a single immunoreceptor tyrosine-based activation motif direct T cells to different fates by balancing effector and memory programs, thereby yielding CAR designs with enhanced therapeutic profiles.
We hypothesized that the redundancy of CD28 and CD3ζ signaling in a chimeric antigen receptor (CAR) design incorporating all three CD3ζ immunoreceptor tyrosine-based activation motifs (ITAMs) 11, 13 may foster counterproductive T cell differentiation and exhaustion 9, 10 . Therefore, we calibrated ITAM activity by mutating tyrosine residues to impede their phosphorylation and downstream signaling [14] [15] [16] [17] . To investigate the contribution of each of the three CD3ζ ITAMs to the function, differentiation, and therapeutic potency of 1928ζ -engineered T cells, we generated single ITAM-containing 1928ζ mutants termed 1XX, X2X, and XX3 (Fig. 1a) . In one additional mutant, termed X23, we retained the two distal ITAMs (ITAM2 and ITAM3), both of which have been shown to display lower binding affinity for tyrosine-protein kinase ZAP-70 relative to ITAM1 13, 18 . All mutant CARs were similarly expressed in retrovirally transduced human peripheral blood T cells (Fig. 1b) ; they were found to direct indistinguishable cytotoxicity in a 4-h chromium-51 ( 51 Cr) release assay and proliferation in response to three weekly stimulations with CD19 antigen (Extended Data Fig. 1a,b) .
Remarkably, the therapeutic efficacy of CAR T cells expressing these mutant CARs differed singularly in the well-established pre-B acute lymphoblastic leukemia Nalm6 mouse model 8, 19, 20 . CAR T cell doses were deliberately lowered to better compare T cell potency, as previously described in the CAR stress test 8 . Relative to the parental 1928ζ , XX3 showed markedly diminished antitumor efficacy, only achieving a transient reduction of tumor burden, whereas 1XX exceeded 1928ζ , inducing long-term remission in all mice ( Thus, while the presence of one (1XX, X2X, XX3), two (X23), or three (1928ζ ) functional ITAMs did not noticeably alter short-term in vitro function, a single ITAM-containing CAR outperformed the triple-and double-ITAM-containing CARs in vivo. Efficacy of tumor eradication gradually decreased with increasing distal positioning of the functional ITAM. The 1XX CAR consistently showed rapid tumor eradication and was the only CAR design to achieve durable and complete remissions at the lowest T cell dose. Treatment with X2X slightly delayed tumor progression compared to wild-type 1928ζ , but relapses eventually developed. The XX3 CAR did not achieve any tumor control, leading to rapid tumor progression and significantly reduced survival ( Fig. 1c and Extended Data Fig. 1c) .
To investigate the functional basis for these major differences in antitumor efficacy, we examined the responses imparted by these CARs in greater depth. In prolonged (18-h ) cytotoxicity assays at a low effector-to-target ratio, XX3 proved to be less active than 1928ζ and the other mutants (Extended Data Fig. 2a) . The diminished effector function of XX3 was further corroborated by reduced granzyme B (GrB) expression (Extended Data Fig. 2b ) and decreased single and polyfunctional type 1 T helper cell (T H 1) cytokine secretion (Extended Data Fig. 2c ) following stimulation with CD19 + targets. Inclusion of a single ITAM (either ITAM1, 2, or 3) limited T cell differentiation as determined by CD62L/CD45RA expression, resulting in an increased fraction of central memory CAR T cells and a reduced proportion of effector cells in response to repeated in vitro stimulation with CD19 + targets (Extended Data Fig. 1d ). These findings were extended in vivo as CAR T cells with two inactive CD3ζ ITAM domains exhibited increased persistence ( Fig. 1d ) and delayed T cell differentiation (Fig. 1e) . 1XX, X2X, and XX3 CAR T cells all demonstrated a higher percentage of CD62L +
CD45RA
− central memory T cells (T CM ) and a decrease in the fraction of terminally differentiated CD62L − CD45RA + effector cells (T EFF ) ( Fig. 1e and Extended Data Fig. 1e ). The attenuation of effector differentiation in CD4
+ and CD8 + CAR T cells was associated with increased accumulation of both T cell subsets at the tumor sites (Fig. 1d) , establishing the benefit of reducing CD3ζ signaling within CD28-based, second-generation CARs. CAR was mutated in one or two of its three ζ signaling domains, named ITAM1, ITAM2, and ITAM3, from a membrane-proximal to a membrane-distal direction. In 1XX, X2X, XX3, and X23 CARs, the two tyrosines (Y) in the respective ITAM are point-mutated to two phenylalanines (F) for the indicated ITAMs. b, Flow cytometric analysis showing expression levels of CAR and LNGFR for the constructs depicted in a. Data are representative of at least five independent experiments with similar results. Untransduced T (UT) cells were used as the control. c-e, Nalm6-bearing mice were treated with 5 × 10 4 CAR + T cells. c, Tumor burden (average radiance) of mice is shown, comparing the in vivo efficacy of wild-type 1928ζ , 1XX, X2X, XX3, and X23 (n = 10 mice per group, results were pooled from two independent experiments). Control refers to untreated mice (n = 6). 
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We next investigated whether the lesser potency of XX3 is intrinsic to ITAM3 or due to its distal position. Therefore, we generated 1928ζ mutant CARs with either ITAM1 or ITAM3 at the same proximal CAR position through deletion of the remaining CD3ζ chain (D12 and D23, Fig. 2a,b) . In vitro studies demonstrated equipotent cytolytic activity between all constructs in 4-and 18-h assays, undiminished cytokine and GrB secretion, and comparable proliferative potential between D12, D23, and 1928ζ (Extended Data Figs. 3 and 4) . However, D12 and D23 both outperformed 1928ζ in vivo, achieving complete tumor eradication ( Fig. 2c and Extended Data Fig. 3d ). Both CAR constructs moderately diminished T cell differentiation and promoted higher CAR T cell accumulation at the tumor site relative to 1928ζ (Fig. 2d,e) .
These findings show the importance of ITAM dosage and position within 1928ζ CARs. A single functional ITAM is sufficient for potent antitumor efficacy and superior to that afforded by the triple-ITAM-containing wild-type CD3ζ chain. Furthermore, the 1928ζ  D12  D23  1928ζ  D12  D23  1928ζ  D12  D23  1928ζ  D12  D23   1928ζ  D12  D23  1928ζ  D12 similar results. UT, untransduced T cells were used as the control. c-e, Nalm6-bearing mice were treated with 5 × 10 4 CAR + T cells. c, Tumor burden (average radiance) of mice treated with wild-type 1928ζ , D12, or D23 (wild-type 1928ζ and D23: n = 10; D12: n = 9; pooled data from two independent experiments). d, Number of CAR T cells in the bone marrow of mice 17 d post-infusion (results were pooled from two independent experiments, n = 10 mice per group). e, Phenotype of CAR T cells in the bone marrow of mice 10 d after CAR infusion, as demonstrated by the percentage of T CM and T EFF cells (pooled data from two independent experiments, n = 10 mice per group). All data are mean ± s.e.m. In d and e, P values were determined by two-tailed Mann-Whitney U-tests. See also Extended Data Figs. 3 and 4.
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therapeutic potency imparted by ITAM3 is less than that of ITAM1 in their respective native positions (XX3 versus 1XX), but comparable at the same proximal position (D12 versus D23). Despite sharing the same ITAM sequence, D12 achieved superior tumor eradication relative to XX3, demonstrating the importance of ITAM location within second-generation CARs. 
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To rule out potentially confounding effects arising from subtly different CAR expression levels, we targeted the CAR complementary DNAs (cDNAs) to the TRAC locus 19 , thereby normalizing transgene regulation and copy number while simultaneously removing the endogenous T cell receptor (TCR; Extended Data Fig. 5a ). Under these conditions, 1XX CAR T cells again surpassed those expressing 1928ζ or XX3 (Fig. 3a) . TRAC-1XX T cells achieved complete remissions within 21 d, while TRAC-XX3 T cells only delayed tumor progression and could not achieve tumor control (Fig. 3a) . Analyses of CAR T cells and tumor cells retrieved 17 d post-CAR infusion showed higher accumulation of TRAC-1XX and TRAC-XX3 CAR T cells compared to TRAC-1928ζ in both CD4
+ and CD8 + subsets ( Fig.  3c and Extended Data Fig. 5b,e) . Increased CAR T cell persistence was associated with a higher percentage of T CM and interleukin-7 receptor (IL7R) + CAR T cell counts (Extended Data Figs. 5c,d ), reinforcing our findings of delayed T cell differentiation in 1928ζ mutants. Similar to retrovirally engineered T cells, TRAC-XX3 T cells lost their cytolytic potential over time in contrast to TRAC-1928ζ and TRAC-1XX cells (Extended Data Fig. 5f ). The expression of exhaustion markers was reduced in 1928ζ mutants compared to TRAC-1928ζ , and functional exhaustion of TRAC-1928ζ was confirmed by reduced T H 1 cytokine secretion and GrB/CD107a expression after CAR isolation from treated mice and ex vivo re-exposure to Nalm6 cells ( Fig. 3d and Extended Data Fig. 6 ). Whereas TRAC-1XX retained high cytolytic function and the capacity of coproducing multiple cytokines, TRAC-1928ζ displayed progressive inability to secrete T H 1 cytokines associated with increased expression of exhaustion markers.
Long-term follow-up studies after administration of two different T cell doses (5 × Fig. 7a-c) , associated with enhanced persistence of highly potent CAR T cells. Importantly, TRAC-1XX CARs were capable of eliciting effective recall responses, achieving complete tumor control following tumor rechallenge (Fig. 3e) . Persisting 1XX CAR T cells comprised increased numbers of T CM , T EFF , and IL7R + CARs (Figs. 3f,g and Extended Data Fig. 7d-f ). In contrast, TRAC-1928ζ more readily acquired an exhausted phenotype ( Fig. 3h and Extended Data Fig. 7g ) accompanied by reduced CAR T cell persistence without memory formation and the inability to control tumor rechallenge.
To further characterize these different phenotypic and functional patterns, we compared the genome-wide transcriptional profiles of 1928ζ , 1XX, and XX3 after CD19 antigen stimulation of TRACedited naive T cells. Principal component analysis demonstrated distinct clustering of CAR T cells dependent on their CD3ζ mutation (Extended Data Fig. 8a) . Consistent with functional studies, major differences emerged in transcriptomic profiles related to T cell function, differentiation, and exhaustion. Gene set enrichment analysis (GSEA) revealed downregulation of naive/memory-associated genes and enrichment of T cell activation-and effector-related genes in 1928ζ relative to both XX3 and 1XX ( Fig. 4a and Extended Data Fig. 8b ). As expected, 1928ζ CAR T cells showed the greatest upregulation of T cell differentiation, exhaustion, and apoptosis gene expression profiles (Fig. 4b,c and Extended data Fig. 9a ). Gene ontology and GSEA analyses identified significant upregulation of the gene sets associated with inflammation, cytokine, and chemokine activity in 1928ζ compared to XX3 and in 1XX compared to XX3 ( Fig. 4c and Extended Data Fig. 9b,c) . These gene sets were also enriched in 1928ζ relative to 1XX, albeit to a lesser extent, consistent with the intermediate status of 1XX relative to 1928ζ and XX3 (Fig. 4b,c and Extended Data Fig. 9b,c) . To compare TRAC-edited CAR T cells to the effector and memory features of nongenetically modified CD8
+ T cell subsets, we sorted naive (T N ), stem cell memory (T SCM ), and T EFF from resting peripheral blood mononuclear cells as their characteristic transcriptional profiles were previously determined 21 (Extended Data Fig. 8c ). Differentially expressed genes (adjusted P < 0.05) associated with effector versus naive/ memory T cell fate distinguished these CAR constructs (Fig. 4b) . Interestingly, TRAC-1XX cells exhibited more similarity to T SCM than TRAC-1928ζ and TRAC-XX3 T cells, which in turn were more similar to T EFF and T N cells, respectively (Fig. 4b) .
Upregulation of key regulators of effector differentiation such as T-bet (and T-bet:Eomes ratio), PR domain zinc finger protein 1 (PRDM1), and DNA-binding protein inhibitor ID-2 (refs. [22] [23] [24] ) with concurrent loss of naive/memory-associated markers (for example, CCR7, CD27, and IL7R
21
) corroborated the rapid acquisition of an effector state seen with 1928ζ ( Fig. 4b and Extended Data Fig. 9c,d ). In contrast, the tuned signaling strength in 1XX resulted in decelerated T cell differentiation and preserved expression of important memory-associated transcription factors, such as transcription factor 7 (TCF7), B-cell lymphoma 6 protein (BCL6), lymphoid enhancer-binding factor 1 (LEF1), and Krüppel-like factor 2 (KLF2) [23] [24] [25] [26] (Fig. 4b ), further reflected in the upregulation of KLF2-regulated genes such as CCR7, CD62L, ITGB7, and S1PR1 (refs. 27, 28 ) ( Fig. 4b and Extended Data Fig. 9d ). While 1XX T cells only demonstrated a partial shift toward a less-differentiated T cell state, XX3 revealed high levels of naive/memory-associated genes together with a systematic suppression of genes encoding master transcription factors for T cell differentiation and effector function ( Fig. 4b-d ). These findings underscore the critical role of ITAM dosage and position to impart different T cell fates. They further support models of memory formation that place cell fate under the control of strength of signaling 24, 29 . Recent reports support the notion that less-differentiated T cell subsets and memory features are associated with increased antitumor potency and persistence of adoptively transferred T cells 30, 31 . Our results extend these findings in demonstrating that T cell differentiation states can be intrinsically controlled by mutations in the CD3ζ chain of CAR T cells. The CD28 and CD3ζ signaling domains are constrained into a 1:1 stoichiometry within CARs 2 , differing from their natural spatiotemporal relationship 11 . Prior I  1928ζ II  1XX III  1XX I  1XX II  XX3 III  XX3 I  XX3 II   TBX21  PRDM1  IKZF2  ZBTB32  ID2  XCL1  XCL2  CSF1  IFNG  TNF  GZMB  PRF1  IL23R  CCL1  CCL3  CCL4  CCL20  CCL22  TNFSF4  TNFRSF9  TNFSF9  CD40LG  CD80  CD83  KLRG1  KLRC1  KLRD1  LAG3  PDCD1  TIGIT  ENTPD1  CTLA4  NR4A3  FASLG  CASP3  POU6F1  BCL6  TCF7  LEF1  KLF2  S1PR1  S1PR4  IL7R  ITGB7  CD27  CXCR3  CXCR4  CCR7 -2 IFNG  TNF  GZMB  PRF1  IL23R  CCL1  CCL3  CCL4  CCL20  CCL22  TNFSF4  TNFRSF9  TNFSF9  CD40LG  CD80  CD83  KLRG1  KLRC1  KLRD1  LAG3  PDCD1  TIGIT  ENTPD1  CTLA4  NR4A3  FASLG  CASP3  POU6F1  BCL6  TCF7  LEF1  KLF2  S1PR1  S1PR4  IL7R  ITGB7  CD27  CXCR3  CXCR4  CCR7   T EFF  T that did not uncover major effects, in contrast to the crucial consequences we uncovered in vivo (Fig. 1) . Our in vivo studies demonstrate that balancing T cell differentiation and acquisition of effector functions is essential to optimize therapeutic potency of CAR T cells based on a comparison of different signaling motifs expressed from a constant genomic locus (Figs. 3 and 4) . We believe this experimental setting to be optimal for quantitative CAR and TCR comparisons 19 . In summary, 1XX induced strong effector functions without shutting off memory programs and outperformed 1928ζ in stress test conditions. Further reducing T cell activation potential through XX3 resulted in highly persisting T cells but mediocre antitumor activity owing to insufficient elicitation of effector functions. Remarkably, the modified ITAM configuration in 1XX favors persistence of highly functional CARs, balancing the replicative capacity of long-lived memory cells and the acquisition of effective antitumor function. Preparations for clinical studies that utilize the 1XX CAR design are underway.
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Methods Cells lines and culture conditions. Nalm6 cells were transduced to express firefly luciferase (FFLuc)-green fluorescent protein (GFP), and murine thymoma EL4 cells and NIH/3T3 cells were transduced to express human CD19 as described previously 8, 20 . Cells were regularly tested for Mycoplasma using the MycoAlert Mycoplasma Detection Kit (Lonza) and found to be negative.
Isolation and expansion of human T cells. Buffy coats from anonymous healthy donors were purchased from the New York Blood Center (institutional review board-exempted) and peripheral blood was obtained from healthy volunteers. All blood samples were handled following the required ethical and safety procedures. Peripheral blood mononuclear cells were isolated by density gradient centrifugation and activated with phytohemagglutinin (2 μ g ml
) for experiments performed with retroviral vectors or T cells were purified using the Pan T Cell Isolation Kit (Miltenyi Biotec) and stimulated with CD3/CD28 T cell Activator Dynabeads (Invitrogen) as described previously 19 and cultured in X-VIVO 15 Serum-free Hematopoietic Cell Medium (Lonza), supplemented with 5% human serum (Gemini Bio-Products), 5 ng ml −1 interleukin-7 (IL7) and 5 ng ml −1 IL15 (BioLegend) for the gene targeting experiments. The medium was changed every 2 d, and cells were plated at 10 6 cells per ml. For some experiments, naive (TCR
and T EFF cells (TCR
were sorted by flow cytometry. The CAR cDNA was then targeted to the TRAC locus of sorted naive T cells, followed by in vitro culture and TCR-negative purification as described later on. Seven days after gene targeting was performed, T cells were stimulated with 3T3-CD19 for 24 h for further analysis or injected into tumor-bearing mice.
Genetic modification of T cells. Plasmids encoding the SFGγ retroviral vector 35
were prepared using standard molecular biology techniques as described previously 20 . Vesicular stomatitis virus glycoprotein G (VSV-G) pseudotyped retroviral supernatants derived from transduced gpg29 fibroblasts (H29) were used to construct stable retroviral-producing cell lines 36 . Synthesis of SFG-1928ζ has been previously described 2, 20, 37 ; it comprises a single-chain variable fragment specific for the human CD19, preceded by a CD8a leader peptide and followed by CD28 hinge-transmembrane-intracellular regions, and CD3ζ or ITAM-mutated/deleted CD3ζ intracellular domains linked to a P2A sequence to induce coexpression of truncated low-affinity nerve growth factor receptor (LNGFR). Standard molecular biology techniques were used to construct the 1928ζ mutants. Tyrosine-to-phenylalanine point mutations within the ITAMs of the CD3ζ chain were introduced to generate 1928ζ CARs with one or two functional ITAMs. For deletion mutations, the membrane-proximal ITAM sequence (ITAM1) was retained or substituted with the membrane-distal ITAM (ITAM3) sequence, and the remaining CD3ζ domain was deleted. 48-h after initiating T cell activation, T cells were transduced with retroviral supernatants by centrifugation on RetroNectin-coated plates (Takara), as described previously. Transduction efficiencies were determined 4 d later by flow cytometry, and CARs were either injected into tumor-bearing mice or used for in vitro experiments.
Gene targeting experiments were performed as described previously 19 . In short, modified guide RNAs (gRNAs) targeting the first exon of the constant chain of the TRA gene 19 and Cas9 messenger RNA (mRNA) were synthesized by TriLink BioTechnologies. The pAAV-TRAC-1928ζ was cloned based on a pAAV-GFP backbone (Cell Biolabs). The pAAV-TRAC-1928ζ contains 1.9 kb of genomic TRAC flanking the gRNA targeting sequences, a self-cleaving P2A peptide in-frame with the first exon of TRAC followed by the 1928ζ or 1928ζ mutant CAR as described earlier. The CAR cDNA is followed by the bovine growth hormone polyA signal.
CD3/CD28 beads were magnetically removed 48 h after initiating T cell activation. T cells were transfected by electrotransfer of Cas9 mRNA and gRNA using an AgilePulse MAX system (BTX) and recombinant AAV6 donor vector (manufactured by SignaGen Laboratories) was added to the culture following electroporation as described previously 19 . To obtain TCR-negative T cells, TCRpositive T cells were removed from the culture using magnetic biotin-anti-TCRα β , anti-biotin microbeads, and LS columns (Miltenyi Biotec).
Cytotoxicity assays. The cytotoxicity of T cells transduced with a CAR was determined by standard 51 Cr release assays and luciferase-based assays. For 51 Cr release assays, EL4 expressing CD19 were used as target cells as described previously 38 . For luciferase-based assays, Nalm6-expressing FFLuc-GFP served as target cells. The effector and tumor target cells were cocultured in triplicates at the indicated effector/ target ratio using black-walled 96-well plates with 5 × 10 4 target cells in a total volume of 100 μ l per well in Nalm6 medium. Target cells alone were plated at the same cell density to determine the maximal luciferase expression (relative light units (RLU)); 18 h later, 100 μ l luciferase substrate (Bright-Glo; Promega) was directly added to each well. Emitted light was detected in a luminescence plate reader. Lysis was determined as (1 − (RLUsample)/(RLUmax)) × 100.
Antigen stimulation and proliferation assays. Four days after transduction, CAR T cells were cocultured with irradiated confluent CD19
+ NIH/3T3, at 6 , 1 × 10 6 or 2 × 10 6 FFLuc-GFP Nalm6 cells at intervals of 7-10 d at the indicated time points. Nalm6 produce very even tumor burdens, and no mice were excluded before treatment. No randomization or blinding methods were used. Bioluminescence imaging was performed using the IVIS Imaging System (PerkinElmer) with the Living Image software (PerkinElmer) for the acquisition of imaging datasets. Tumor burden was assessed as described previously 39 .
RNA extraction, transcriptome sequencing and RNA-seq analysis. Seven days after gene targeting of sorted naive T cells was performed, TRAC-1928ζ , TRAC-XX3, and TRAC-1XX were stimulated with irradiated 3T3-CD19 for 24 h, followed by magnetic selection of CD8 + cells (Miltenyi Biotec). Washed T cells were resuspended in 250 μ l PBS and placed in 750 μ l TRIzol LS Reagent (Thermo Fisher Scientific). RNA was extracted using the RNeasy Mini Kit (QIAGEN) according to the instructions provided by the manufacturer. After RiboGreen RNA quantification and quality control using an Agilent Bioanalyzer, 500 ng of total RNA underwent polyA selection and TruSeq RNA library preparation according to the instructions provided by the manufacturer (TruSeq Stranded mRNA LT Kit; Illumina), with eight cycles of PCR. Samples were barcoded and run on a HiSeq 4000 (Illumina) in a 50 base pair (bp)/50 bp paired-end run, using the HiSeq 3000/4000 SBS Kit (Illumina). An average of 30.6 million paired reads was generated per sample. At the most, the ribosomal reads represented 4.69% of the total reads generated; the percentage of mRNA bases averaged 69.3%.
The output FASTQ data were mapped to the target genome using the STAR RNA-seq aligner (version 2.5.0a; two-pass method) 40 , resolving reads across splice junctions. The first mapping pass uses a list of known annotated junctions from Ensemble (https://www.ensembl.org/index.html). Junctions found during the first pass are then added to the known junctions and a second mapping pass is done using the RemoveNoncanonical flag. After mapping, the output SAM files (SAMtools, version 0.1.19) were processed using PICARD tools (version 1.124; https://broadinstitute.github.io/picard/) to add read groups and AddOrReplaceReadGroups, which in addition sorts the file and converts it to the compressed BAM format. The expression count matrix was then computed from the mapped reads using HTSeq (version 0. Differentially expressed genes between T cell subsets (T N , T CM , T SCM , T EFF cells) were retrieved from Gattinoni et al.
21
. GSEA was performed using a pre-ranked file generated using log 2 (fold change) on curated pathway gene sets from the Broad Institute Molecular Signature Database (http://www.broadinstitute.org/gsea/ msigdb/). The gene signatures demonstrated are derived from immunological signatures C7, Reactome, KEGG and gene ontology (Biological Process) gene sets. GSE41867 was used for the GSEA of exhausted versus naive/memory CD8 T cells and to curate the signature of 200 genes upregulated in exhausted CD8 T cells (day 30 post-lymphocytic choriomeningitis virus infection) relative to memory and naive cells. Genes identified as differentially expressed between experimental conditions, with an adjusted P value < 0.05 and absolute log 2 (fold change) > 1, were used for gene ontology analysis using the R package enrichR (http://amp.pharm. mssm.edu/Enrichr/).
Antibodies and intracellular staining. The following fluorophore-conjugated antibodies were used. From BD Biosciences: APC-Cy7 mouse anti-human CD8; APC-Cy7 mouse anti-human CD45; BUV395 mouse anti-human CD4; PE mouse anti-human CD4; BB515 mouse anti-human CD4; BV421 mouse anti-human CD62L; BV650 mouse anti-human CD45RA; BV421 mouse anti-human CD45RA; BV480 mouse anti-human CD279 (PD-1); BV650 mouse anti-human CD279 (PD-1); BUV737 mouse anti-human CD19; BV421 mouse anti-human TIM3 (CD366); BB515 mouse anti-human CD95; APC-H7 mouse anti-human CD27; PE mouse anti-human CD271 (LNGFR). From BioLegend: APC anti-human CD8a; APC/Cy7 anti-human CD62L; FITC anti-human CD45RA; Brillian Violet 785 anti-human CD366 (Tim-3); PE anti-human CD127 (IL-7Rα ); Alexa Fluor 488 anti-human CD127 (IL-7Rα ); PerCP/Cyanine5.5 anti-human CD197 (CCR7); Brilliant Violet 650 anti-human CD28. From Invitrogen: CD8a Monoclonal Antibody (RPA-T8), PE-Cyanine7; CD223 (LAG-3) monoclonal antibody (3DS223H) PerCP-eFluor 710; CD223 (LAG-3) Monoclonal Antibody (3DS223H), APC; InvitrogenTCR alpha/beta monoclonal antibody (IP26), PE-Cyanine7. From Miltenyi Biotec:
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by two-tailed paired Student's t-tests for matched samples. For in vivo experiments, the overall survival was depicted by a Kaplan-Meier curve and the log-rank test was used to compare survival differences between the groups. P values < 0.05 were considered to be statistically significant. The statistical test used for each figure is described in the corresponding figure legend.
Reporting Summary. Further information on research design is available in the Nature Research Reporting Summary linked to this article.
Data availability
The RNA-seq data have been deposited in the Gene Expression Omnibus and are available under accession number GSE121226. Raw data for the figures in the manuscript will be made available upon request to the corresponding author. For intracellular cytokine secretion assay, T cells were cocultured with 3T3-CD19 or Nalm6 in the presence of the Golgi Plug protein transport inhibitor (BD Biosciences) for the last 4 h. For CD107a staining, Brilliant Violet 650 anti-human CD107a (LAMP-1) antibody (BioLegend) was added to the coculture. For ex vivo cytokine analyses, CAR T cells were obtained from the bone marrow and spleen of treated mice and purified using a mouse cell depletion kit (Miltenyi Biotec). Samples were processed in biological triplicates (d16) or pooled (due to low cell numbers in 1928ζ -treated mice), and technical triplicates (d36) were performed. Stimulation with phorbol myristate acetate (PMA)/ionomycin (Invitrogen) were performed as the positive control. T cells were subsequently washed, stained for cell surface markers, fixed, and permeabilized according to the manufacturer's instructions using a Cytofix/Cytoperm Fixation/Permeabilization Solution Kit (BD Biosciences). Intracellular cytokine staining was performed with BV421 rat anti-human IL2, BV650 mouse anti-human TNF, BUV395 mouse anti-human TNF, BUV395 mouse anti-human IFN-γ , or FITC mouse anti-human IFN-γ (all BD Biosciences), and APC or PE granzyme B monoclonal antibody (GB12, both Invitrogen).
References
Flow cytometry was performed on a LSR II or LSRFortessa instrument (BD Biosciences) and a FACSAria sorter (BD Biosciences) was used for cell sorting. Data were analyzed with the FlowJo software v.10.1 (FlowJo LLC).
Statistical analysis.
All statistical analyses were performed using the Prism 7 (GraphPad) software. No statistical methods were used to predetermine sample size. Statistical comparisons between two groups were determined by two-tailed parametric or nonparametric (Mann-Whitney U-test) t-tests for unpaired data or + target cells (n = 3 independent experiments). All data are means ± s.e.m.; P values were calculated with two-tailed paired Student's t-test. c, Cytotoxic activity of D12 and D23 compared to wild-type 1928ζ as determined by 18-h bioluminescence assay with FFL-expressing NALM6 cells as targets. Experiments were performed 1 week after expansion of effector cells on CD19 + target cells. Data are means ± s.e.m. (n = 4 independent experiments performed in triplicates). P value was calculated by two-tailed paired Student's t-test of average of triplicates and showed no significant difference (P > 0.05) between D12/D23 and wild-type 1928ζ for all E/T ratios. d, NALM6-bearing mice were treated with 5 × 10 4 CAR T cells. Kaplan-Meier analysis of survival of mice treated with wild-type 1928ζ or indicated 1928ζ mutants (n = 10 mice per group). Control refers to untreated mice (n = 6). P value was calculated by a one-sided log-rank Mantel-Cox test. sTnaive_III_CD8_18  sTnaive_II_CD8_17  sTnaive_I_CD8_25  sTnaive_II_CD8_26  sTnaive_I_CD8_16  sTnaive_III_CD8_27  sTEFF_III_CD8_15  sTEFF_III_CD8_24  sTEFF_I_CD8_22  sTEFF_II_CD8_23  sTEFF_I_CD8_13  sTEFF_II_CD8_14  sTSCM_III_CD8_12  sTSCM_II_CD8_20  sTSCM_I_CD8_10  sTSCM_II_CD8_11  sTSCM_I_CD8_19  sTSCM_III_CD8_21   F A NCD2  GPA33  MDN1  RASA3  WNT7A  SORBS3  F A M65B  DSC1  LDHB  CCNE1  TPP2  T A CC3  ARHGEF18  SMAP2  PKIA  NELL2  CEP68  RIC3  TBC1D15  SGTB  ITPKB  GCNT4  SELL  LEF1  ZSWIM1  SPTBN1  ARHGEF11  TCEA3  ACTN1  MAL  APP  PTK2  TMEM120B  RGMB  PPARD  TSHZ2  DGKA  NPA T  PELO  ZNF418  NMU  FAAH2  C16orf45  F A M69A  IL4R  SFXN1  SESN3  SELP  ZC3H12D  MT1F  STRADB  PELI1  PTK7  PROS1  HAVCR1  GOL T 1B  NUP88  NUP35  ZNF121  TWISTNB  UTP20  DMXL2  ZNF101  ACBD4  SLC40A1  TIMM8A  L T V1  CDNF  NAP1L1  DCBLD2  L Y RM5  RBM11  LRP6  SFMBT2  THG1L  RPS3A  ZFAND1  FCHO1  ZC3H12B  FUBP1  ERCC1  TMOD2  MPZL1  WDR27  ACTR5  FUS  FBXW8  ZNF268  SCARB2  RBM43  TMEM41B  OCRL  PIGV  ITGB7  RNF44  EDAR  LRRC7  SPPL2B  CHML  TSP A N32  SFXN4  NRCAM  MEST  GATM  TPST1  TMEM220  ZNF135  AGBL3  NMNAT3  MYO15B  RBM26  ZNF506  LBH  P A K1  ARRB1  MMP28  PDHX  SNORA5C  EIF1AX  SLC7A8  RIN3  INPP5A  IGF1R  F A M63A  LDLRAP1  TTTY14  MRM1  CHMP7  ZNF563  LMO7  RPL10A  EPHX2  IL6ST  MAN1C1  F A M117B  T A F4B  CDCA7L  GRAP  RASGRP2  UXS1  APBA2  HS3ST3B1  DENND2D  EEF2K  FCGBP  CHKA  CRTC3  CAD  PPARGC1B  TIMD4  BZW2  JAGN1  SNRNP70  T A RBP1  A T M  STXBP1  VIPR1  UBASH3B  KIAA1958  EIF2B4  TMPO  NUDCD3  XPO6  HBS1L  GIPC3  AEBP1  AKR1B1  TSEN2  KAT2A  C16orf74  SLC16A10  GJB6  MLXIP  KCNQ1  NOL6  USP51  TO P1MT  ALPK1  LGMN  SLC22A17  SNRK  SNORA54  RAB43  FLNB  MRPS33  WDR89  PRKAR1B  KLHL3  PPFIBP2  PITPNM2  GAL3ST4  NOG  UBE2E2  HSF2  RAPGEF6  LAS1L  TNFRSF10D  HLA DOA  FOXP1  SDK2  LRRN1  FRMD7  NDUFS2  RHOH  ANAPC13  KCTD12  RPP25  MPI  BEND5  LARS  PIM2  PCY O X1L  FCER1G  KDM6B  UBASH3A  NUMA1  KRT72  KRT73  PTPN6  PBX3  KCNQ5  CACHD1  PTPRK  DEPDC7  C3orf18  PDK1  SEC14L2  JAK3  CRLF3  AP1M1  NUCB2  HES1  GPSM3  ENPP2  MED28  GNAI1  MARCKSL1  ZSCAN23  ABCB8  OLFM2  MET A P2  PSIP1  CCDC102B  PYGB  ZNF540  SUL T 1B1  AK5  F A M175A  FGD3  ANKRD31  CNN3  USP53  ACSS2  NBEA  SEH1L  BCL9  CYP2J2  ZNF347  HNRNPUL1  NETO2  PHACTR2  GALM  DUSP2  NBEAL2  TCIRG1  ERN1  MBOAT1  PNPLA6  SV2A  TSEN54  COP A  KIF3B  TTC39C  MINK1  GTPBP1  ZBTB1  CHAC1  EDARADD  PYHIN1  TNIP3  SLAMF7  SYNE2  F A S  PIK3R1  SLAMF1  RU NX3  SYTL3  TNFRSF1B  EOMES  AHNAK  CST7  TIP A RP  MTCH2  BRE  ANXA2  PPP2R5C  A T XN1  ARAP2  LRP8  CD58  TPRG1  ANK3  IL2RB  SRGN  LRIG1  METRNL  GIT2  FTH1  CLDND1  EPHA4  RGS2  GPRIN3  ST6GALNAC2  CCL5  GZMK  SMAD3  TNF A IP3  SP140  LAG3  F2R  HMGB3  TSP A N18  TO M1  CALD1  IGSF9B  CDH1  MCOLN3  MAP3K1  GPR15  QPCTL  COTL1  CHN1  ARID5B  ENTPD1  OGDH  GPR183  EVC  AGFG2  CCR4  CHEK1  RILPL2  CNOT 6L  HCN3  NCAPH  MYO1C  WEE1  IQGAP2  F A M129A  JOSD1  USP46  NEK6  DGKH  ST8SIA1  SYT11  MCOLN2  TIGIT  CEP97  ITGB1  IRF4  Y A RS  PPP1R15A  MBP  SFXN3  STA T 5B  FLOT 1  SLC27A2  KPNA2  OSBPL5  KIAA0040  IFI6  SCARNA5  MBNL3  FKBP11  RORA  KLRF1  PLD1  PLXNC1  CD151  IL15RA  NEO1  CXCR6  IL18RAP  ITCH  RIPK1  CLIP4  SYTL2  ABL1  SCARNA17  GALNT1  GALNT10  ZBTB44  OGFRL1  CIDEB  AGAP2  ARHGAP10  ERMP1  MATN1  AXIN1  SPA T A2L  NRG2  C14orf80  MMP19  USH2A  NANOS2  TNIP1  TYMP  IFI16  RASGRP1  LGALS1  SCD5  CD300A  V A NGL1  DPYSL2  GLUL  TBCD  RAB1B  MYH9  CTDSP1  JAZF1  GNL Y  LPIN2  NR4A3  ICAM1  C4orf50  PPP2R2B  TGFBI  SPIRE2  ZSCAN22  GALK1  NCR1  CD244  SASH3  CPT1A  DENND3  GALNT3  C3AR1  PRF1  NHSL2  ST8SIA6  C12orf75  GTDC1  ZEB2  CHST12  S1PR5  AKNA  VWCE  ALO X 5AP  CLSPN  C11orf63  STK3  IDS  ARF3  NEK3  NR3C1  CD69  PRKCI  TBC1D5  SHKBP1  ANKS1A  F A M160B1  DUSP4  PEA15  FUCA2  OSBPL3  RAPGEF1  IL12RB1  TBC1D2B  CHD9  AK1  HLA DRB5  SETD2  SLFN11  CBF A 2T2  GLCCI1  APOBEC3G  SLA2  FASLG  ABI3  GAB3  PLCD1  DLG5  CYP4F22  CAMK2N1  PIP4K2A  B4GAL T 5  ZFYVE28  ULBP3  TMX4  PIK3CG  HEG1  FCHO2  C1orf21  SLFN12L  KLRG1  MAPK1  ADRB2  PTGDR  WIPF1  YPEL1  DMPK  OSBPL7  BCL2L1  APOBEC3F  ARHGAP18  MATK  WIPI1  NPC1  SLC4A4  RASGEF1A  MICAL2  CCR3  CADM1  CYTH3  MSC  HIP1  GZMA  TMEM39A  NRM  SLC6A6  CNNM3  TGFB1  REEP5  ZC3HA V 1L  TRAF6  MXD4  KLRB1  ABCA2  MYBL1  MAN1A1  PTPRM  UEVLD  THBS1  ADCY9  CMIP  LIMK1  CRIM1  AU TS2  GYG1  P A RP8  SPA T S2L  FRMD4B  GFPT2  PIK3AP1  PTPN22  ANTXR2  PMAIP1  FOSL2  GCNT1  F A DS3  CD68  PLEKHA2  FHOD1  CDK2AP1  PIWIL4  CDCA4  RDX  MVD  CSRP1  GABARAPL1  MAP4  PPP3CA  KLF6  PTPRJ  CALHM2  ZC3H12A  ARHGEF12  DUSP10  PI4K2A  KLRD1  TBK1  DCBLD1  STOM  CACNB1  BMPR1A  ANXA2P2  MAP3K5  RAB27A  LPGAT1  MXRA7  LRP10  SOX13  PLXND1  CLCF1  RNF166  MYO1F  RNF19A  FOXP4  LPCAT4  A T G2A  ADAM8  SH2D2A  GBP2  PTGER2  TBX21  F A M46C  ACOT9  CLIC1  MFSD10  ARL6IP1  STX11  ITPR3  GPR153  TLR3  GBP5  TBKBP1  NTNG2  REL  P A M  RALGDS  F A NCA  CACNB3  RAB27B  TMEM43  LCP1  MYO6  PRR5L  PCBP4  GNAO1  SYNE1  EMB  SLC1A4  KATNAL1  TLN1  F A M53B  CAPN2  LLGL2  CTNNA1  PPP4R1  ANXA5  DLG3  TOX  PPP1R16B  APOBEC3D  A T P2B4  GGA2  WSB2  NF1  ST6GALNAC6  CHST11  TGFBR3  IQGAP1  PRDM1  MEF2D  MAF  MYO5A  DNAJC1  ACTN4  APOBEC3C  A T G4D  IRF1  RAB11FIP4  PIK3R3  REEP4  MYL6  SEL T  YWHAQ  ST7  CLSTN3  TP53INP1  BTG3  ARL4C  PLEKHA5   4   2   0   2   4   TN_1_GSM572425  TN_2_GSM572429  TN_3_GSM572433  TEM_1_GSM572424  TEM_2_GSM572428  TEM_3_GSM572432  TCM_1_GSM572423  TCM_2_GSM572427  TCM_3_GSM572431  TSCM_1_GSM572422  TSCM_2_GSM572426  TSCM_3_GSM572430   F A NCD2  GPA33  MDN1  FLJ41327  RASA3  WNT7A  SORBS3  F A M65B  DSC1  LDHB  CCNE1  TPP2  T A CC3  ARHGEF18  SMAP2  PKIA  NELL2  CEP68  RIC3  TBC1D15  SGTB  ITPKB  GCNT4  SELL  LEF1  ZSWIM1  SPTBN1  ARHGEF11  TCEA3  ACTN1  MAL  APP  PTK2  TMEM120B  RGMB  PPARD  TSHZ2  DGKA  NPA T  PELO  ZNF418  NMU  KRT A P5 2  CWH43  F A AH2  C16orf45  F A M69A  RBM46  IL4R  SFXN1  SESN3  SELP  ZC3H12D  MT1F  STRADB  PELI1  PTK7  PROS1  TDRD6  HAVCR1  GOL T 1B  NUP88  NUP35  ZNF121  TWISTNB  UTP20  DMXL2  ZNF101  ACBD4  SLC40A1  TIMM8A  L T V1  CDNF  NAP1L1  DCBLD2  L Y RM5  RBM11  LRP6  SFMBT2  THG1L  RPS3A  ZFAND1  FCHO1  ZC3H12B  FUBP1  ERCC1  TMOD2  MPZL1  WDR27  SNORA55  ACTR5  FUS  FBXW8  ZNF268  SCARB2  RBM43  TMEM41B  OCRL  PIGV  ITGB7  LOC100128288  RNF44  EDAR  LRRC7  SPPL2B  CHML  TSP A N32  SFXN4  NRCAM  MEST  GATM  TPST1  TMEM220  ZNF135  AGBL3  NMNAT3  MYO15B  RBM26  ZNF506  LBH  P A K1  ARRB1  MMP28  PDHX  SNORA5C  EIF1AX  SLC7A8  RIN3  INPP5A  IGF1R  F A M63A  LDLRAP1  TTTY14  MRM1  CHMP7  ZNF563  LMO7  RPL10A  EPHX2  IL6ST  MAN1C1  F A M117B  T A F4B  CDCA7L  GRAP  RASGRP2  UXS1  APBA2  HS3ST3B1  DENND2D  EEF2K  FCGBP  CHKA  CRTC3  CAD  PPARGC1B  TIMD4  BZW2  JAGN1  SNRNP70  T A RBP1  A T M  STXBP1  VIPR1  UBASH3B  KIAA1958  EIF2B4  TMPO  NUDCD3  XPO6  HBS1L  GIPC3  AEBP1  AKR1B1  TSEN2  KAT2A  C16orf74  SLC16A10  GJB6  MLXIP  KCNQ1  NOL6  USP51  TO P1MT  ALPK1  LGMN  SLC22A17  SNRK  SNORA54  RAB43  FLNB  MRPS33  WDR89  PRKAR1B  KLHL3  PPFIBP2  PITPNM2  GAL3ST4  NOG  UBE2E2  HSF2  RAPGEF6  LAS1L  TNFRSF10D  HLA DOA  FOXP1  SDK2  LRRN1  FRMD7  NDUFS2  RHOH  ANAPC13  KCTD12  RPP25  MPI  BEND5  LARS  PIM2  PCY O X1L  FCER1G  KDM6B  UBASH3A  NUMA1  KRT72  KRT73  PTPN6  PBX3  KCNQ5  CACHD1  PTPRK  DEPDC7  C3orf18  PDK1  SEC14L2  JAK3  CRLF3  AP1M1  NUCB2  HES1  GPSM3  ENPP2  MED28  GNAI1  MARCKSL1  ZSCAN23  A T CAY  ABCB8  OLFM2  METAP2  PSIP1  CCDC102B  PYGB  ZNF540  SUL T 1B1  AK5  F A M175A  FGD3  ANKRD31  CNN3  USP53  ACSS2  NBEA  SEH1L  BCL9  CYP2J2  ZNF347  HNRNPUL1  NETO 2  PHACTR2  GALM  DUSP2  NBEAL2  TCIRG1  ERN1  MBOAT1  PNPLA6  SV2A  TSEN54  COP A  KIF3B  TTC39C  MINK1  GTPBP1  ZBTB1  CHAC1  EDARADD  PYHIN1  TNIP3  SLAMF7  SYNE2  F A S  PIK3R1  SLAMF1  RUNX3  CD99  SYTL3  TNFRSF1B  EOMES  AHNAK  CST7  TIP A RP  MTCH2  BRE  ANXA2  PPP2R5C  ATXN1  ARAP2  LRP8  CD58  TPRG1  ANK3  IL2RB  SRGN  LRIG1  METRNL  GIT2  FTH1  CLDND1  EPHA4  RGS2  GPRIN3  ST6GALNAC2  CCL5  GZMK  SMAD3  TNF A IP3  SP140  LAG3  F2R  HMGB3  TSP A N18  TO M1  CALD1  IGSF9B  CDH1  MCOLN3  MAP3K1  GPR15  QPCTL  COTL1  CHN1  ARID5B  ENTPD1  OGDH  GPR183  EVC  AGFG2  IL9R  CCR4  CHEK1  RILPL2  CNOT 6L  HCN3  NCAPH  MYO1C  WEE1  IQGAP2  F A M129A  JOSD1  USP46  NEK6  P2RY 8  DGKH  ST8SIA1  SYT11  MCOLN2  TIGIT  CEP97  ITGB1  IRF4  Y A RS  PPP1R15A  PKHD1  MBP  SFXN3  STA T 5B  FLOT 1  SLC27A2  KPNA2  OSBPL5  KIAA0040  IFI6  SCARNA5  MBNL3  FKBP11  RORA  KLRF1  PLD1  PLXNC1  CD151  IL15RA  NEO1  CXCR6  IL18RAP  ITCH  RIPK1  CLIP4  SYTL2  ABL1  SCARNA17  GALNT1  GALNT10  F A M159B  ZBTB44  OGFRL1  CIDEB  AGAP2  ARHGAP10  T A RP  ERMP1  MATN1  AXIN1  SP A T A2L  NRG2  C14orf80  MMP19  C7  USH2A  NANOS2  TNIP1  TYMP  IFI16  RASGRP1  ZAK  LGALS1  SCD5  CD300A  V A NGL1  DPYSL2  GLUL  TBCD  RAB1B  MYH9  CTDSP1  JAZF1  GNL Y  LPIN2  NR4A3  ICAM1  C4orf50  PPP2R2B  TGFBI  SPIRE2  ZSCAN22  GALK1  NCR1  CD244  SASH3  CPT1A  DENND3  GALNT3  C3AR1  PRF1  NHSL2  ST8SIA6  C12orf75  GTDC1  ZEB2  CHST12  S1PR5  AKNA  VWCE  ALO X 5AP  CLSPN  C11orf63  STK3  IDS  ARF3  NEK3  NR3C1  CD69  PRKCI  TBC1D5  SHKBP1  ANKS1A  F A M160B1  DUSP4  PEA15  FUCA2  OSBPL3  RAPGEF1  IL12RB1  TBC1D2B  CHD9  AK1  HLA DRB5  SETD2  SLFN11  CBF A 2T2  GLCCI1  APOBEC3G  SLA2  F A SLG  ABI3  GAB3  PLCD1  DLG5  CYP4F22  CAMK2N1  PIP4K2A  B4GAL T 5  ZFYVE28  ULBP3  TMX4  PIK3CG  HEG1  FCHO2  C1orf21  SLFN12L  KLRG1  MAPK1  ADRB2  PTGDR  WIPF1  YPEL1  DMPK  OSBPL7  BCL2L1  APOBEC3F  ARHGAP18  MATK  WIPI1  NPC1  SLC4A4  RASGEF1A  MICAL2  CCR3  CADM1  CYTH3  MSC  HIP1  GZMA  TMEM39A  NRM  SLC6A6  CNNM3  TGFB1  REEP5  ZC3HA V 1L  TRAF6  MXD4  KLRB1  ABCA2  MYBL1  MAN1A1  PTPRM  UEVLD  THBS1  ADCY9  CMIP  LIMK1  CRIM1  AU TS2  GYG1  PARP8  SPA T S2L  FRMD4B  GFPT2  PIK3AP1  PTPN22  ANTXR2  PMAIP1  FOSL2  GCNT1  F A DS3  CD68  PLEKHA2  FHOD1  CDK2AP1  PIWIL4  CDCA4  RDX  MVD  CSRP1  GABARAPL1  MAP4  PPP3CA  KLF6  PTPRJ  CALHM2  ZC3H12A  ARHGEF12  DUSP10  PI4K2A  KLRD1  TBK1  DCBLD1  STOM  CACNB1  BMPR1A  ANXA2P2  MAP3K5  RAB27A  LPGAT1  MXRA7  LRP10  SOX13  PLXND1  CLCF1  RNF166  MYO1F  RNF19A  FOXP4  LPCAT4  A T G2A  ADAM8  SH2D2A  GBP2  PTGER2  TBX21  F A M46C  ACOT9  CLIC1  MFSD10  ARL6IP1  STX11  ITPR3  GPR153  TLR3  GBP5  TBKBP1  NTNG2  REL  P A M  RALGDS  F A NCA  CACNB3  RAB27B  TMEM43  LCP1  MYO6  PRR5L  PCBP4  GNAO1  SYNE1  EMB  SLC1A4  KATNAL1  TLN1  F A M53B  CAPN2  LLGL2  CTNNA1  PPP4R1  ANXA5  DLG3  TOX  PPP1R16B  APOBEC3D  ATP2B4  GGA2  WSB2  NF1  ST6GALNAC6  CHST11  TGFBR3  IQGAP1  PRDM1  MEF2D  MAF  MYO5A  DNAJC1  ACTN4  APOBEC3C  A T G4D  IRF1  RAB11FIP4  PIK3R3  REEP4  MYL6  SEL T  YWHAQ  ST7  CLSTN3  TP53INP1  BTG3  ARL4C  PLEKHA5   2   1   0   1   2   Tnaive  TEM  TCM  TSCM  Tnaive  TEFF Fig. 8 | Transcriptional profiles of TRAC-encoded 1928ζ mutants and sorted control T cells. a, Principal component analysis (PCA I  XX3 II  1XX II  1XX I  1XX III  1928z III  1928z I  1928z II   XCL1   XCL2   IFNG   TNF   IL1A   IL2   IL3   IL5   IL11   IL13   IL23A   IL18R1   IL21R   IL23R   EBI3   IL31   CSF1   CSF2   CCL1   CCL3   CCL4   CCR4   CCL3L1   CCL4L2   CCL17 
Extended Data
Statistical parameters
When statistical analyses are reported, confirm that the following items are present in the relevant location (e.g. figure legend, table legend, main text, or Methods section).
n/a Confirmed
The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement An indication of whether measurements were taken from distinct samples or whether the same sample was measured repeatedly
The statistical test(s) used AND whether they are one-or two-sided
Only common tests should be described solely by name; describe more complex techniques in the Methods section.
A description of all covariates tested A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons A full description of the statistics including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)
For null hypothesis testing, the test statistic (e.g. F, t, r) with confidence intervals, effect sizes, degrees of freedom and P value noted For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors/reviewers upon request. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Research guidelines for submitting code & software for further information.
Data
Policy information about availability of data All manuscripts must include a data availability statement. This statement should provide the following information, where applicable:
-Accession codes, unique identifiers, or web links for publicly available datasets -A list of figures that have associated raw data -A description of any restrictions on data availability
The RNA-seq data have been deposited in the Gene Expression Omnibus (GEO) and are available under the accession number GSE121226. The datasets generated during the current study are available from the corresponding author upon reasonable request.
#115-606-072). 7-AAD (BD, #559925, lot no: 7081885) and LIVE/DEAD Fixable Violet (L34963, Invitrogen) were used as a viability dyes. Antibodies were validated by the manufacturer for flow cytometric applications and titrated for optimal staining. 
Mycoplasma contamination
All cell lines were routinely tested for mycoplasma and were found to be negative.
Commonly misidentified lines (See ICLAC register)
No commonly misidentified cell lines were used.
Animals and other organisms
Policy information about studies involving animals; ARRIVE guidelines recommended for reporting animal research Buffy coats from anonymous healthy donors were purchased from the New York Blood Center. The researchers were blind to any covariate characteristics.
Recruitment
There was no recruitment of participants. Buffy coats were purchased from the New York Blood Center as described.
Flow Cytometry Plots
Confirm that:
The axis labels state the marker and fluorochrome used (e.g. CD4-FITC).
The axis scales are clearly visible. Include numbers along axes only for bottom left plot of group (a 'group' is an analysis of identical markers).
All plots are contour plots with outliers or pseudocolor plots.
A numerical value for number of cells or percentage (with statistics) is provided.
Methodology Sample preparation
Buffy coats from anonymous healthy donors and peripheral blood from healthy volunteers were isolated and purified as described in Methods. Splenic mice cells were obtained by physical dissociation of the spleen on a cell strainer. Cells were washed with PBS/2mM EDTA off the strainer and collected in a tube. Bone marrow cells were collected from femurs. Muscles surrounding the femur were removed and bones were crushed in a mortar with addition of PBS/2mM EDTA, passed through a cell strainer and collected in a tube. Cells were pelleted and red blood cells were lysed with the addition of ACK lysis buffer and subsequently washed. For ex vivo cytokine analyses, CAR T cells were obtained from bone marrow and spleen of treated mice and purified using mouse cell depletion kit (Miltenyi). Cells were subsequently washed, resuspended in FACS Buffer with Fc blocking reagent; antibodies were added and washed off after the incubation time. If intracellular staining was performed, cells were fixed and permeabilized using the Cytofix/Cytoperm kit (BD Biosciences) according to the manufacturer's instructions. If cells were counted, counting beads (Invitrogen) were added in the final cell suspension to quantify cells. 
